Evonik Shares Tumble After BASF Ends $12 Billion Takeover Efforts — Update
By Sarah Sloat and Adria Calatayud
German chemicals giant BASF said it dropped its efforts to acquire Evonik Industries, abandoning a deal that could have exceeded $12 billion and sending shares in the target company sharply lower.
BASF said it decided to walk away after Evonik's rejection of two offers, ending its attempt to snap up one of its smaller domestic rivals to better compete with chemicals groups from Asia and the Middle East.
Shares in Evonik were down 17% at 18.14 euros in European afternoon trading, coming back to roughly the level they traded at before BASF's takeover interest became public in September. BASF shares were up slightly.
"Despite the indication that BASF was prepared to consider a further moderate increase to its offer, the Executive Board of Evonik has not shown meaningful engagement until today," BASF said in a statement.
BASF also said that an assessment of Evonik's standalone prospects and risks didn't justify a higher valuation.
"Against this background, BASF does not consider it to be in the best interests of its shareholders to pursue the transaction at a higher price," it said.
Evonik didn't immediately respond to a request for comment. Last month, the company said it decided not to enter into negotiations as it focused on delivering its standalone strategy, but that its executives were willing to discuss their position with BASF on a purely informational and confidential basis.
In response, BASF said at the time that it was surprised Evonik's executive board wasn't prepared to discuss its offer. The bid valued Evonik at 11.18 billion euros ($12.27 billion), based on a per-share price of 24 euros and share-count data provided by FactSet.
The companies first disclosed their talks in September, triggering a rally in Evonik's shares.
BASF Chief Executive Officer Markus Kamieth said last month that he saw a strong chemical industry in Germany as the right response to global competition, calling out the progress rivals from Asia and the Middle East were making amid growing headwinds for the industry.
Kamieth vowed to respect Evonik's existing labor agreements and ruled out compulsory redundancies until 2032. As part of a bigger group, Evonik would be able to get feedstocks cheaper and more reliably, while benefiting from other advantages in procurement, infrastructure, and research, he added.
Write to Sarah Sloat at sarah.sloat@wsj.com and to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
November 19, 2026 10:39 ET (15:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

The 10 Best Dividend Stocks

This Newly Undervalued Stock Has Plenty of Growth Ahead

